Effect of dehydroepiandrosterone administration on fatigue, well-being, and functioning in women with primary Sjogren syndrome: a randomised controlled trial

A. Hartkamp; R. Geenen; G. L. R. Godaert; H. Bootsma; A. A. Kruize; J. W. J. Bijlsma; R. H. W. M. Derksen

doi:10.1136/ard.2007.071563

Effect of dehydroepiandrosterone administration on fatigue, well-being, and functioning in women with primary Sjogren syndrome: a randomised controlled trial

A. Hartkamp, R. Geenen^*, G. L. R. Godaert, H. Bootsma, A. A. Kruize, J. W. J. Bijlsma, R. H. W. M. Derksen

^*Corresponding author for this work

Translational Immunology Groningen (TRIGR)

Research output: Contribution to journal › Article › Academic › peer-review

86 Citations (Scopus)

Abstract

Objective: Dehydroepiandrosterone (DHEA) administration has been reported to improve fatigue, psychological distress, and physical disability. These are common features of primary Sjogren syndrome (pSS). We investigated the effects of DHEA administration on fatigue, well-being, and functioning in women with pSS.

Methods: In a double-blind, randomised placebo-controlled clinical trial, 60 female patients with pSS received 200 mg oral DHEA or placebo. Primary outcome measures were general fatigue, depressive mood, mental well-being, and physical functioning. In addition, pain, sicca complaints and disease activity parameters were measured. Patients were assessed before treatment, after 3, 6, and 12 months on study medication, and 6 months after cessation of treatment.

Results: Patients from both the DHEA-and placebo-treated group improved on general fatigue (p

Conclusions: Our study does not support a superior effect of DHEA over placebo in female patients with pSS. Both DHEA and placebo induce improvement of fatigue and well-being. This may suggest possibilities for cognitive behavioural interventions.

Original language	English
Pages (from-to)	91-97
Number of pages	7
Journal	Annals of the Rheumatic Diseases
Volume	67
Issue number	1
DOIs	https://doi.org/10.1136/ard.2007.071563
Publication status	Published - Jan-2008

Keywords

SYSTEMIC-LUPUS-ERYTHEMATOSUS
PLACEBO-CONTROLLED TRIAL
DOUBLE-BLIND
CLASSIFICATION CRITERIA
PSYCHOMETRIC QUALITIES
REPLACEMENT THERAPY
ANDROGEN-DEFICIENT
CLINICAL-TRIAL
ELDERLY-WOMEN
DHEA

Access to Document

10.1136/ard.2007.071563

Handle.net

Persistent link

Cite this

@article{b891535bade74eeea5166b33328fbe73,

title = "Effect of dehydroepiandrosterone administration on fatigue, well-being, and functioning in women with primary Sjogren syndrome: a randomised controlled trial",

abstract = "Objective: Dehydroepiandrosterone (DHEA) administration has been reported to improve fatigue, psychological distress, and physical disability. These are common features of primary Sjogren syndrome (pSS). We investigated the effects of DHEA administration on fatigue, well-being, and functioning in women with pSS.Methods: In a double-blind, randomised placebo-controlled clinical trial, 60 female patients with pSS received 200 mg oral DHEA or placebo. Primary outcome measures were general fatigue, depressive mood, mental well-being, and physical functioning. In addition, pain, sicca complaints and disease activity parameters were measured. Patients were assessed before treatment, after 3, 6, and 12 months on study medication, and 6 months after cessation of treatment.Results: Patients from both the DHEA-and placebo-treated group improved on general fatigue (pConclusions: Our study does not support a superior effect of DHEA over placebo in female patients with pSS. Both DHEA and placebo induce improvement of fatigue and well-being. This may suggest possibilities for cognitive behavioural interventions.",

keywords = "SYSTEMIC-LUPUS-ERYTHEMATOSUS, PLACEBO-CONTROLLED TRIAL, DOUBLE-BLIND, CLASSIFICATION CRITERIA, PSYCHOMETRIC QUALITIES, REPLACEMENT THERAPY, ANDROGEN-DEFICIENT, CLINICAL-TRIAL, ELDERLY-WOMEN, DHEA",

author = "A. Hartkamp and R. Geenen and Godaert, \{G. L. R.\} and H. Bootsma and Kruize, \{A. A.\} and Bijlsma, \{J. W. J.\} and Derksen, \{R. H. W. M.\}",

year = "2008",

month = jan,

doi = "10.1136/ard.2007.071563",

language = "English",

volume = "67",

pages = "91--97",

journal = "Annals of the Rheumatic Diseases",

issn = "0003-4967",

publisher = "BMJ Publishing Group",

number = "1",

}

TY - JOUR

T1 - Effect of dehydroepiandrosterone administration on fatigue, well-being, and functioning in women with primary Sjogren syndrome

T2 - a randomised controlled trial

AU - Hartkamp, A.

AU - Geenen, R.

AU - Godaert, G. L. R.

AU - Bootsma, H.

AU - Kruize, A. A.

AU - Bijlsma, J. W. J.

AU - Derksen, R. H. W. M.

PY - 2008/1

Y1 - 2008/1

N2 - Objective: Dehydroepiandrosterone (DHEA) administration has been reported to improve fatigue, psychological distress, and physical disability. These are common features of primary Sjogren syndrome (pSS). We investigated the effects of DHEA administration on fatigue, well-being, and functioning in women with pSS.Methods: In a double-blind, randomised placebo-controlled clinical trial, 60 female patients with pSS received 200 mg oral DHEA or placebo. Primary outcome measures were general fatigue, depressive mood, mental well-being, and physical functioning. In addition, pain, sicca complaints and disease activity parameters were measured. Patients were assessed before treatment, after 3, 6, and 12 months on study medication, and 6 months after cessation of treatment.Results: Patients from both the DHEA-and placebo-treated group improved on general fatigue (pConclusions: Our study does not support a superior effect of DHEA over placebo in female patients with pSS. Both DHEA and placebo induce improvement of fatigue and well-being. This may suggest possibilities for cognitive behavioural interventions.

AB - Objective: Dehydroepiandrosterone (DHEA) administration has been reported to improve fatigue, psychological distress, and physical disability. These are common features of primary Sjogren syndrome (pSS). We investigated the effects of DHEA administration on fatigue, well-being, and functioning in women with pSS.Methods: In a double-blind, randomised placebo-controlled clinical trial, 60 female patients with pSS received 200 mg oral DHEA or placebo. Primary outcome measures were general fatigue, depressive mood, mental well-being, and physical functioning. In addition, pain, sicca complaints and disease activity parameters were measured. Patients were assessed before treatment, after 3, 6, and 12 months on study medication, and 6 months after cessation of treatment.Results: Patients from both the DHEA-and placebo-treated group improved on general fatigue (pConclusions: Our study does not support a superior effect of DHEA over placebo in female patients with pSS. Both DHEA and placebo induce improvement of fatigue and well-being. This may suggest possibilities for cognitive behavioural interventions.

KW - SYSTEMIC-LUPUS-ERYTHEMATOSUS

KW - PLACEBO-CONTROLLED TRIAL

KW - DOUBLE-BLIND

KW - CLASSIFICATION CRITERIA

KW - PSYCHOMETRIC QUALITIES

KW - REPLACEMENT THERAPY

KW - ANDROGEN-DEFICIENT

KW - CLINICAL-TRIAL

KW - ELDERLY-WOMEN

KW - DHEA

U2 - 10.1136/ard.2007.071563

DO - 10.1136/ard.2007.071563

M3 - Article

SN - 0003-4967

VL - 67

SP - 91

EP - 97

JO - Annals of the Rheumatic Diseases

JF - Annals of the Rheumatic Diseases

IS - 1

ER -

Effect of dehydroepiandrosterone administration on fatigue, well-being, and functioning in women with primary Sjogren syndrome: a randomised controlled trial

Abstract

Keywords

Access to Document

Handle.net

Fingerprint

Cite this